Donato Russo, MD
Obstetrics & Gynecology · Union, NJNPI 1427073311
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Celularity Inc. at 37.1% of the total. Reporting peaked in 2019 at $1,364 and has fallen 98.6% since, to $19 in 2023.
Across 145 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$1K
- Therapeuticsmd, Inc.$345
- AbbVie$207
- AMAG Pharmaceuticals, Inc.$198
- Pfizer$165
- Lupin Inc.$156
- plus $964 from 20 others
What the payments were for
- Speaking & faculty fees$1,20037%
- Food & beverage$1,78655%
- Education$2317%
- Gifts$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 4 | $1,200 |
| Therapeuticsmd, Inc. | 23 | $345 |
| AbbVie(2 entities) | 15 | $207 |
| AMAG Pharmaceuticals, Inc. | 14 | $198 |
| Pfizer | 12 | $165 |
| Lupin Inc. | 11 | $156 |
| Millicent US Inc | 9 | $126 |
| Agile Therapeutics, Inc. | 8 | $116 |
| Exeltis, USA Inc. | 7 | $96 |
| Vertical Pharmaceuticals, LLC | 6 | $84 |
| Myovant Sciences Inc. | 5 | $72 |
| Evofem Biosciences, Inc. | 5 | $72 |
| Amgen | 5 | $65 |
| Mylan Pharmaceuticals Inc. | 3 | $44 |
| Avion Pharmaceuticals | 3 | $40 |
| Convatec Inc. | 1 | $33 |
| Mayne Pharma Commercial LLC | 2 | $30 |
| Merck | 2 | $29 |
| Hologic Sales And Service, LLC | 2 | $29 |
| Duchesnay USA Incorporated | 2 | $27 |
| Bayer | 1 | $22 |
| Roche Diagnostics Corporation | 1 | $19 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Scynexis, Inc. | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $15 |
| Medicem Inc. | 1 | $13 |
How this compares
$3,234 in reported general payments places this provider in the 85th percentile of 1,242 obstetrics & gynecology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Risedronate Sodium | 27 | $2,584 |
| Estradiol | 38 | $2,370 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Union
- Jennifer AshtonEnglewood$1.5M
- Geoffrey BowersVoorhees$228K
- Neha DeshpandePlainsboro$206K
- Paula JasionowskiVoorhees$193K
- Justin ChuraSwedesboro$179K
- Andrea VentolaFlorham Park$145K
- Aiman ShiladPaterson$100K
- Patrick CulliganMorristown$93K
- Dipak DelvadiaCherry Hill$86K
- Susan PitmanWest Orange$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.